SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $24,100.00 in Stock

Posted by Bonnie Powley on May 1st, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $4.82, for a total value of $24,100.00. Following the completion of the transaction, the insider owned 261,388 shares of the company’s stock, valued at approximately $1,259,890.16. This represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,161.60.
On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $7,936.00.
On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,944.00.
On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total value of $17,433.00.
On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,152.94.
On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total value of $13,552.00.
On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total value of $11,688.00.
On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $13,095.00.
On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH opened at $5.22 on Friday. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a 12 month low of $2.59 and a 12 month high of $5.70. The stock has a 50 day moving average of $4.81 and a 200-day moving average of $4.77. The company has a market capitalization of $357.52 million, a P/E ratio of -10.24 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The business had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. BTIG Research lifted their target price on SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Guggenheim lifted their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $7.50.

Read Our Latest Stock Analysis on SOPHiA GENETICS

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently added to or reduced their stakes in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. lifted its holdings in SOPHiA GENETICS by 16.4% during the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after purchasing an additional 31,000 shares during the last quarter. Akre Capital Management LLC lifted its holdings in SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC acquired a new stake in SOPHiA GENETICS during the 3rd quarter worth approximately $6,708,000. Finally, Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS during the 3rd quarter worth approximately $48,000. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.